Biohaven Ltd. (NYSE:BHVN – Get Free Report) rose 9.6% on Thursday after JPMorgan Chase & Co. raised their price target on the stock from $14.00 to $35.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. Biohaven traded as high as $13.94 and last traded at $14.1350. Approximately 295,513 shares traded hands during mid-day trading, a decline of 89% from the average session volume of 2,742,931 shares. The stock had previously closed at $12.90.
A number of other equities research analysts have also issued reports on BHVN. Robert W. Baird set a $48.00 price target on Biohaven in a research report on Thursday, October 22nd. TD Cowen reiterated a “buy” rating on shares of Biohaven in a research report on Wednesday, August 26th. HC Wainwright reissued a “neutral” rating and set a $10.00 price objective on shares of Biohaven in a research note on Thursday, September 10th. Canaccord Genuity Group upped their target price on Biohaven from $21.00 to $32.00 and gave the company a “buy” rating in a report on Friday, October 30th. Finally, Wall Street Zen cut Biohaven from a “hold” rating to a “sell” rating in a report on Saturday, November 7th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, four have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Biohaven currently has an average rating of “Moderate Buy” and a consensus target price of $22.57.
Check Out Our Latest Report on BHVN
Key Biohaven News
Here’s some of the latest news about BHVN:
- Positive Sentiment: In an ongoing Phase 1 study, 6 of 10 evaluable patients treated at doses of at least 3.3 mg/kg responded to BHV-1530, including 3 of 5 with urothelial cancer and all 3 with HPV-positive head and neck cancer. The responses support further development of the FGFR3-targeted drug candidate. Biohaven BHV-1530 Phase 1 results
- Positive Sentiment: JPMorgan raised its price target from $14 to $35 and maintained an Overweight rating, reflecting a more optimistic analyst view. JPMorgan recommendations
- Neutral Sentiment: The encouraging response results come from a small, early-stage patient group. BHV-1530 remains investigational, so larger studies will be needed to establish how reliable and durable the benefit is.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the company. Allworth Financial LP raised its holdings in shares of Biohaven by 10.4% in the 3rd quarter. Allworth Financial LP now owns 8,672 shares of the company’s stock valued at $116,000 after purchasing an additional 814 shares in the last quarter. Integrated Wealth Concepts LLC lifted its position in shares of Biohaven by 8.4% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 13,716 shares of the company’s stock worth $183,000 after purchasing an additional 1,063 shares during the last quarter. Inspire Investing LLC lifted its position in shares of Biohaven by 2.4% during the 3rd quarter. Inspire Investing LLC now owns 47,089 shares of the company’s stock worth $629,000 after purchasing an additional 1,113 shares during the last quarter. IFP Advisors Inc grew its stake in shares of Biohaven by 43.3% during the second quarter. IFP Advisors Inc now owns 6,011 shares of the company’s stock worth $89,000 after purchasing an additional 1,816 shares in the last quarter. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors grew its stake in shares of Biohaven by 12.9% during the third quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors now owns 17,500 shares of the company’s stock worth $234,000 after purchasing an additional 2,000 shares in the last quarter. Hedge funds and other institutional investors own 88.78% of the company’s stock.
Biohaven Trading Down 9.5%
The company has a debt-to-equity ratio of 21.23, a current ratio of 3.05 and a quick ratio of 3.05. The business’s 50 day moving average is $13.42 and its 200 day moving average is $12.38. The stock has a market cap of $1.87 billion, a price-to-earnings ratio of -3.20 and a beta of 1.36.
About Biohaven
Biohaven Ltd. is a clinical-stage biopharmaceutical company developing treatments for neurological, immunological and other serious diseases. Its research programs include potential therapies for epilepsy and autoimmune conditions, as well as medicines designed to target disease-related proteins and antibodies. The company’s pipeline includes investigational candidates that act on ion channels and immune pathways. These programs are in development and are not approved medicines; Biohaven does not have a marketed product portfolio.
Further Reading
- Five stocks we like better than Biohaven
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
Receive News & Ratings for Biohaven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven and related companies with MarketBeat.com's FREE daily email newsletter.
